Microba Life Sciences Limited (ASX:MAP) has confirmed that its proposed merger with Genetic Signatures Limited (ASX:GSS) will not proceed, after GSS resolved to abandon the transaction following Microba's disclosure that it lacks the financial capacity to complete the merger without additional capital.

Key Points

  • GSS resolved not to proceed with the proposed merger after Microba disclosed it would not have financial capacity to complete the transaction without additional capital.
  • Tranche 2 of Microba's institutional placement, announced on 20 October 2026, was unable to proceed because Microba could not satisfy the conditions to the placement.
  • Microba requested a voluntary suspension of trading in its securities on 17 November 2026 while exploring funding options.
  • Microba stated it is continuing to assess its cashflow position and exploring funding options while remaining in voluntary suspension.

Proposed Merger Termination Details

According to the filing dated 18 November 2026, Genetic Signatures Limited announced on the same date that it had resolved not to proceed with the proposed merger with Microba Life Sciences. The decision followed Microba's disclosure that it would not have the financial capacity to complete the proposed merger without additional capital. As a direct consequence, the company confirmed the proposed merger will not proceed. The filing describes the outcome as disappointing, noting it follows many months of discussions, engagement and due diligence, and that Microba had been working on options to obtain alternative funding.

Institutional Placement Conditions and Capital Requirements

The filing states the requirement for additional capital arose from Tranche 2 of Microba's institutional placement, which was announced to the ASX on 20 October 2026, not being able to proceed. The placement could not proceed on the basis that revisions to the indicative terms of the proposed merger, while considered generally commercially acceptable to the Microba Board, were such that Microba could not satisfy the conditions to the placement. The filing does not disclose the specific revised terms or the quantum of capital sought under Tranche 2 of the placement.

Voluntary Suspension and Funding Assessment

Microba disclosed that it had requested a voluntary suspension of trading in its securities on 17 November 2026 while exploring funding options. The company stated in the filing that, notwithstanding the proposed merger not progressing, it is continuing to assess its cashflow position and exploring its options for funding while it remains in voluntary suspension. The filing does not specify a timeline for the voluntary suspension to be lifted or detail any particular funding options currently under consideration by the company.